ReviewBlood reviews2021
The looming storm: Blood and cytokines in COVID-19.
Review in Blood reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Bowel ischemia in COVID-19: A systematic review.International journal of clinical practice · 2021Pooled it
- The potential role of indomethacin in COVID-19 management: A systematic review of therapeutic and mechanistic evidence.New microbes and new infections · 2026Review
- Serum Calprotectin in Hospitalized Patients with COVID-19 in Relation to High-Dimensional Serum Proteomic Patterns.International journal of molecular sciences · 2026Observational
- Hematological and biochemical markers for predicting severity in COVID-19 patients.BMC infectious diseases · 2026Observational
- Impact of SARS-CoV-2 variants and vaccination on pediatric febrile seizures: a retrospective cohort study.BMC pediatrics · 2025Article
- Association between enteral essential fatty acids and plasma phospholipid essential fatty acids related immune response in critically ill adults with COVID-19: A prospective cohort study.JPEN. Journal of parenteral and enteral nutrition · 2025Article
- Cytokine Storm in a Massively Burned Pediatric Patient.Journal of burn care & research : official publication of the American Burn Association · 2025Article
- Ferroptosis and Metabolic Dysregulation: Emerging Chemical Targets in Cancer and Infection.Molecules (Basel, Switzerland) · 2025Review
- Hematological Markers in Thromboembolic Events: A Comparative Study of COVID-19 and Non-COVID-19 Hospitalized Patients.Journal of clinical medicine · 2025Article
- Early Driving Pressure Is Associated with Major Adverse Kidney Events at 30 Days in ARDS Patients with SARS-CoV-2.Journal of clinical medicine · 2025Article
- Review
- ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow.Thrombosis and haemostasis · 2024Article
- Dynamic lymphocyte-CRP ratio as a predictor: a single-centre retrospective study on disease severity and progression in adult COVID-19 patients.The Journal of international medical research · 2024Article
- Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study.Infectious diseases & clinical microbiology · 2024Article
- Case report: unprecedented case of infantile cerebral infarction following COVID-19 and favorable outcome.Frontiers in immunology · 2024Article
- Algorithms for predicting COVID outcome using ready-to-use laboratorial and clinical data.Frontiers in public health · 2024Article
- Plasma essential fatty acid on hospital admission is a marker of COVID-19 disease severity.Scientific reports · 2023Article
- Multi-Omic Candidate Screening for Markers of Severe Clinical Courses of COVID-19.Journal of clinical medicine · 2023Article
- Reconstructing the cytokine view for the multi-view prediction of COVID-19 mortality.BMC infectious diseases · 2023Article
- Identifying potential pharmacological targets and molecular pathways of Meliae cortex for COVID-19 therapy.Frontiers in immunology · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel coronavirus termed as COVID-19 by WHO has been the causative agent of an unprecedented pandemic in the history of humanity. The global burden of mortality and morbidity associated with this pandemic continues to increase with each passing day as it is progressively leading to multiorgan dysfunction. In most cases, the cause of death has been attributed to respiratory failure, sepsis, cardiac failure, kidney injury, or coagulopathy. As more knowledge is being unfolded, an in-depth understanding of various systemic manifestations and complications of SARS-CoV2 is vital for optimum management of these patients. This novel virus is known to spread faster than its two ancestors, the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), demonstrating a case fatality ranging from 5 to 8% [1]. Hematological abnormalities such as lymphopenia, thrombocytopenia, elevated D-Dimer, elevated fibrinogen, elevated fibrinogen degradation products as well as cytokines such as IL-6 are emerging as important prognostic marker for worse outcome of COVID-19. Among various systemic manifestations, hematological complications such as venous thrombosis causing pulmonary embolism or deep vein thrombosis, and arterial thrombosis causing myocardial infarction, strokes or limb ischemia are being noted to be directly linked to high mortality from COVID-19. An attempt to understand the pathophysiology of various hematological abnormalities including cytokine storm, hypercoagulable state and some rare presentations of this disease hence becomes imperative. Through this review, we aim to provide an up-to-date summary of current evidence-based literature of hematological manifestations, their consequences and management including role of anticoagulation and drugs targeting cytokine storm in patients with SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.